

Special Issue

Sarcopenia and Frailty as a Prognostic/Outcome Biomarker of Urological Cancer Patients

Message from the Guest Editors

Sarcopenia is a condition characterized by the degenerative and systemic loss of skeletal muscle mass with the reduction of skeletal muscle strength and physical performance. Sarcopenia reflects not only the frailty of the host and intolerance to cancer therapy but also the presence of cancer cachexia. Thus, sarcopenia is one of the most clinically important factors in the management of cancer-bearing patients. In the field of urological cancers, including urothelial cancer, kidney cancer, and prostate cancer, a growing number of studies have shown the strong prognostic value of sarcopenia in association with therapeutic modalities according to the disease extent. Currently, minimally invasive robotic surgery is becoming a mainstay of urological cancer surgery. This Special Issue of *Cancers* focuses on the role of sarcopenia as a prognostic biomarker of urological cancer patients in contemporary clinical practice. This special issue also covers frailty as a treatment outcome biomarker of those patients.

Guest Editors

Dr. Fumitaka Koga

Department of Urology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan

Dr. Hiroshi Fukushima

Department of Urology, Tokyo Medical and Dental University, Tokyo, Japan

Deadline for manuscript submissions

closed (15 October 2023)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/114596

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)